Noida, Uttar Pradesh, India, May 2026 – Jubilant Pharmova Limited has announced the appointment of Ashish Mukkirwar as Chief Financial Officer. In his new role, he will lead the company’s financial strategy, capital management, and financial leadership initiatives as the organization continues to strengthen its global pharmaceutical and healthcare operations.
A seasoned finance and strategy leader, Ashish Mukkirwar brings extensive experience across pharmaceuticals, investment banking, corporate finance, investor relations, and strategic transformation.
Prior to joining Jubilant Pharmova Limited, Ashish Mukkirwar served at Glenmark Pharmaceuticals, where he most recently held the position of Group Vice President & CFO – Global Formulations Business. During his tenure, he played a significant role in financial leadership, business strategy, and driving operational and commercial priorities for the company’s global formulations business. Earlier at Glenmark, he also served as Group Vice President – Strategy and Investor Relations, leading strategic planning and investor engagement initiatives.
Before entering the pharmaceutical sector, Ashish built a strong foundation in global investment banking and corporate advisory. He spent over eight years with Moelis & Company across progressively senior roles including Executive Director, Vice President, and Associate, advising clients on mergers & acquisitions, capital raising, and strategic transactions. His experience included working with leading organizations on complex financial and business transformation initiatives.
Earlier in his career, he was associated with UBS as Associate Director, Investment Banking, where he worked on multiple capital market fundraising and M&A transactions, particularly across the technology and consumer sectors. He also briefly served with Violet Arch in a strategic finance leadership role.
Ashish began his professional journey with Infosys as a Software Engineer, where he gained experience in project coordination, offshore delivery management, and enterprise technology execution before transitioning into finance and management leadership.
An alumnus of Indian Institute of Management Calcutta, where he completed his PGDM in Finance, Ashish combines strong financial acumen with strategic and operational expertise across global business environments.
About Jubilant Pharmova Limited
Jubilant Pharmova Limited is a global integrated pharmaceutical company engaged across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Proprietary Novel Drugs businesses.
The company operates a broad international footprint with manufacturing facilities serving regulated markets including the United States, Europe, and several global regions. Its businesses span radiopharmaceutical manufacturing and supply, allergy therapeutics, sterile injectables manufacturing, drug discovery services, APIs, and innovative biopharmaceutical research in oncology and autoimmune disorders.
With approximately 5,500 employees globally, Jubilant Pharmova continues to advance healthcare innovation through science, technology, and precision-driven execution.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work